Q2 2025 · 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLCholdings as filed
Filed 2025-08-14 · accession 0001420506-25-002146
$542.3M
Reported value
65
Positions
2025-06-30
Period end
The Brief · SILVERARC CAPITAL MANAGEMENT, LLC · Q2 2025
AI · grounded in 13F
SILVERARC CAPITAL MANAGEMENT, LLC established a new position in MERUS N V 2GH valued at $39.0M. The fund also initiated new stakes in AKERO THERAPEUTICS INC AKRO for $38.1M and VERONA PHARMA PLC VRNA for $33.9M. Additional new positions include UROGEN PHARMA LTD URGN at $27.7M and RHYTHM PHARMACEUTICALS INC RYTM at $25.3M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $39.0M | 7.20% | 741,972 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $38.1M | 7.02% | 713,811 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $33.9M | 6.25% | 358,297 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $27.7M | 5.11% | 2,022,482 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $25.3M | 4.67% | 400,772 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $25.1M | 4.62% | 249,060 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $20.7M | 3.82% | 1,832,171 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $20.5M | 3.78% | 162,969 | Common | SOLE |
| N5749R900 | — | MERUS N V | $20.1M | 3.71% | 382,500 | CALL | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $20.0M | 3.69% | 2,037,087 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $18.3M | 3.37% | 1,800,829 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $18.0M | 3.31% | 235,583 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $17.1M | 3.16% | 204,591 | Common | SOLE |
| 78464A900 | — | SPDR SERIES TRUST | $16.6M | 3.06% | 200,000 | CALL | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $14.9M | 2.75% | 86,552 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $14.1M | 2.59% | 541,034 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $12.1M | 2.24% | 448,495 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $12.1M | 2.23% | 341,010 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $11.6M | 2.15% | 410,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $9.4M | 1.73% | 287,796 | Common | SOLE |
| 717081103 | PFE | PFIZER INC | $8.3M | 1.54% | 344,338 | Common | SOLE |
| 670703907 | NUVL | NUVALENT INC | $7.6M | 1.41% | 100,200 | CALL | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $6.5M | 1.20% | 613,393 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $6.3M | 1.17% | 5,146,782 | Common | SOLE |
| 59267L107 | — | METSERA INC | $5.9M | 1.09% | 207,581 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $5.5M | 1.01% | 2,761,684 | Common | SOLE |
| M25722105 | CGEN | COMPUGEN LTD | $5.4M | 1.00% | 3,033,879 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $5.4M | 0.99% | 2,779,795 | Common | SOLE |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $5.2M | 0.96% | 917,898 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $5.1M | 0.93% | 103,943 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $4.0M | 0.74% | 198,441 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $3.9M | 0.72% | 286,807 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $3.9M | 0.71% | 82,023 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $3.8M | 0.70% | 402,964 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $3.6M | 0.67% | 175,636 | Common | SOLE |
| 19239V902 | CCOI | COGENT COMMUNICATIONS HLDGS | $3.6M | 0.66% | 500,000 | CALL | SOLE |
| 157085101 | CERS | CERUS CORP | $3.5M | 0.65% | 2,488,291 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $3.3M | 0.60% | 2,569,591 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $3.2M | 0.60% | 1,249,781 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $3.2M | 0.60% | 186,015 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $3.0M | 0.55% | 253,234 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $3.0M | 0.54% | 539,587 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $2.8M | 0.52% | 202,565 | Common | SOLE |
| 433000956 | HIMS | HIMS & HERS HEALTH INC | $2.5M | 0.46% | 50,000 | PUT | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $2.1M | 0.39% | 75,959 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $1.9M | 0.34% | 165,389 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $1.8M | 0.33% | 95,806 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $1.7M | 0.32% | 109,257 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $1.6M | 0.29% | 115,282 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $1.5M | 0.28% | 401,540 | Common | SOLE |
| 14070B959 | CAPR | CAPRICOR THERAPEUTICS INC | $1.4M | 0.26% | 144,700 | PUT | SOLE |
| 24661P807 | DCTH | DELCATH SYS INC | $1.4M | 0.26% | 103,026 | Common | SOLE |
| 00973Y908 | AKRO | AKERO THERAPEUTICS INC | $1.3M | 0.25% | 25,000 | CALL | SOLE |
| 59045L106 | MRSN | MERSANA THERAPEUTICS INC | $926,013 | 0.17% | 3,128,421 | Common | SOLE |
| 75041J101 | RADX | RADIOPHARM THERANOSTICS LTD | $869,564 | 0.16% | 187,406 | Common | SOLE |
| 60785L207 | — | MODULAR MED INC | $529,220 | 0.10% | 710,363 | Common | SOLE |
| 87164F905 | SNDX | SYNDAX PHARMACEUTICALS INC | $468,000 | 0.09% | 50,000 | CALL | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $420,500 | 0.08% | 10,000 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $328,196 | 0.06% | 202,590 | Common | SOLE |
| 09075X108 | BDSX | BIODESIX INC | $302,058 | 0.06% | 1,070,367 | Common | SOLE |
| 786700104 | SGMT | SAGIMET BIOSCIENCES INC | $286,047 | 0.05% | 37,539 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $200,600 | 0.04% | 10,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $65,700 | 0.01% | 5,000 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $8,941 | 0.00% | 346 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $3,019 | 0.00% | 104,828 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.